GO:0045907 positive regulation of vasoconstriction: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045907 (positive regulation of vasoconstriction) describes any biological process that activates or increases the frequency, rate, or extent of vasoconstriction, the narrowing of blood vessels.
• This process is essential for blood pressure control, organ perfusion, and cardiovascular homeostasis, and its dysregulation contributes to hypertension, heart failure, and other vascular disorders [1,6,7].
• Key molecular players include DAPK1, which acts as a positive regulator of hypertension via induction of vasoconstriction, and the renin-angiotensin-aldosterone system, where aldosterone antagonism improves outcomes in heart failure.
• Nitric oxide (NO) is a major counter-regulatory vasodilator; loss of NO bioavailability enhances vasoconstriction and is implicated in septic shock and other pathologies.
• Ageing and sex significantly impact sympathetic neurocirculatory regulation, thereby modulating vasoconstrictor responses.
• Research tools such as CRISPR knockout, knock-in, and overexpression models, combined with physiological measurements, are critical for dissecting the genetic basis of vasoconstriction regulation [1,7].
Description
Positive regulation of vasoconstriction (GO:0045907) is a biological process that enhances the narrowing of blood vessels, a fundamental mechanism for regulating blood pressure and blood flow distribution. This process is tightly controlled by neural, hormonal, and local factors, and its dysregulation is a hallmark of cardiovascular diseases such as hypertension and heart failure [1,6]. Understanding the molecular players and signaling pathways that positively regulate vasoconstriction is essential for developing targeted therapies. Recent studies have identified DAPK1 as a positive regulator of hypertension via induction of vasoconstriction, highlighting the importance of this GO term in disease pathogenesis. Additionally, the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system are classical regulators, with aldosterone antagonism showing benefits in heart failure. Nitric oxide (NO) acts as a counter-regulatory vasodilator, and its impairment can shift the balance toward enhanced vasoconstriction, as seen in septic shock. Ageing and sex also influence sympathetic neurocirculatory regulation, further modulating vasoconstrictor tone. This article provides a comprehensive overview of GO:0045907, covering its definition, mechanisms, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based models for functional studies.
positive regulation of vasoconstriction At A Glance
| GO ID | GO:0045907 |
|---|---|
| GO term | positive regulation of vasoconstriction |
| Ontology | biological_process |
| Synonym | activation of vasoconstriction, stimulation of vasoconstriction, up regulation of vasoconstriction, up-regulation of vasoconstriction, upregulation of vasoconstriction |
| Major function | Enhances vasoconstriction, contributing to blood pressure regulation and organ perfusion |
| Related processes | Vasoconstriction, blood pressure regulation, smooth muscle contraction, sympathetic nervous system activity |
| Key regulators | DAPK1, angiotensin II, aldosterone, endothelin-1, sympathetic nerves |
| Disease relevance | Hypertension, heart failure, septic shock, pulmonary hypertension |
What Is GO:0045907?
According to the Gene Ontology, GO:0045907 (positive regulation of vasoconstriction) is defined as any process that activates or increases the frequency, rate or extent of vasoconstriction. In other words, it encompasses all molecular events and pathways that lead to enhanced narrowing of blood vessels, whether through increased smooth muscle contraction, reduced vasodilatory signals, or other mechanisms. This term is a child of 'regulation of vasoconstriction' and is distinct from negative regulation, which would decrease vasoconstriction.
Why Is positive regulation of vasoconstriction Important in Cell Biology?
Positive regulation of vasoconstriction is critically important because it directly influences blood pressure, tissue perfusion, and cardiovascular homeostasis. Dysregulation of this process can lead to hypertension, heart failure, and other vascular disorders, making it a prime target for therapeutic intervention [1,6]. Understanding the molecular mechanisms that enhance vasoconstriction can reveal novel drug targets and biomarkers for disease management.
• Controls blood pressure and blood flow distribution to vital organs.
• Dysregulation contributes to hypertension, a major risk factor for stroke and heart attack.
• Plays a role in heart failure progression, where aldosterone antagonism improves outcomes.
• Involved in septic shock, where excessive vasoconstriction or vasodilation can be detrimental.
• Modulated by ageing and sex, affecting cardiovascular risk profiles.
• Nitric oxide counter-regulates vasoconstriction; its impairment enhances vasoconstrictor tone.
• Renal autoregulation depends on balanced vasoconstriction and vasodilation.
• Hypoxic pulmonary vasoconstriction is a protective mechanism but can become pathological.
• Provides targets for CRISPR-based functional genomics and drug discovery.
What Happens During positive regulation of vasoconstriction?
Initiation by Vasoconstrictor Agonists
In simple terms: Certain molecules like angiotensin II or endothelin-1 bind to receptors on smooth muscle cells and trigger a cascade that makes blood vessels tighten.
Positive regulation of vasoconstriction often begins with the binding of vasoconstrictor agonists such as angiotensin II, aldosterone, or endothelin-1 to their respective receptors on vascular smooth muscle cells. This binding activates intracellular signaling pathways, including G-protein coupled receptor signaling and calcium mobilization, leading to increased intracellular calcium concentrations [1,6]. For example, DAPK1 has been shown to act as a positive regulator of hypertension via induction of vasoconstriction, likely through modulation of calcium signaling or contractile machinery.
Smooth Muscle Cell Contraction
In simple terms: The smooth muscle cells in the vessel wall contract, narrowing the vessel and increasing blood pressure.
The rise in intracellular calcium activates myosin light chain kinase (MLCK), which phosphorylates myosin light chains, promoting actin-myosin cross-bridge cycling and smooth muscle contraction. This contraction reduces the vessel lumen diameter, increasing vascular resistance and blood pressure. Positive regulation of this step can occur through enhanced calcium sensitization or increased expression of contractile proteins [1,7].
Neural and Hormonal Modulation
In simple terms: Nerves and hormones can amplify the tightening of blood vessels.
The sympathetic nervous system releases norepinephrine, which binds to alpha-adrenergic receptors on vascular smooth muscle, enhancing vasoconstriction. Ageing and sex influence sympathetic neurocirculatory regulation, thereby modulating vasoconstrictor responses. Hormonal factors such as aldosterone promote sodium retention and can directly sensitize vessels to vasoconstrictors; aldosterone antagonism has been shown to benefit heart failure patients.
Counter-Regulation by Nitric Oxide
In simple terms: Nitric oxide normally relaxes blood vessels, so when it is reduced, vasoconstriction is enhanced.
Nitric oxide (NO) produced by endothelial NO synthase (eNOS) diffuses to smooth muscle cells and activates soluble guanylate cyclase, leading to cGMP-mediated vasodilation. Positive regulation of vasoconstriction can occur when NO bioavailability is reduced, as seen in septic shock where excessive NO production causes vasodilation, but impaired NO signaling can also enhance vasoconstriction. Thus, the balance between NO and vasoconstrictors determines net vascular tone.
Integration in Renal and Pulmonary Circulation
In simple terms: In organs like the kidney and lungs, vasoconstriction is fine-tuned to maintain function.
Renal autoregulation relies on the myogenic response and tubuloglomerular feedback, both involving positive regulation of vasoconstriction to maintain constant glomerular filtration rate. In the pulmonary circulation, hypoxic pulmonary vasoconstriction diverts blood from poorly ventilated areas to optimize oxygenation; this process can be inhibited by carbon monoxide. These examples highlight the context-dependent nature of positive regulation of vasoconstriction.
Key Genes Involved in GO:0045907 positive regulation of vasoconstriction
The following genes and proteins are key players in the positive regulation of vasoconstriction, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DAPK1 | Positive regulator of hypertension via induction of vasoconstriction | Potential target for antihypertensive therapy; studied in KO and overexpression models |
| AGTR1 | Angiotensin II receptor type 1; mediates vasoconstriction | Target of ARBs; CRISPR KO models to study blood pressure regulation |
| EDN1 | Endothelin-1; potent vasoconstrictor | Implicated in pulmonary hypertension; KO models available |
| NOS3 | Endothelial nitric oxide synthase; produces NO, a vasodilator | Counter-regulates vasoconstriction; KO mice show hypertension |
| REN | Renin; rate-limiting enzyme in RAAS | Involved in angiotensin II production; KO models for hypertension research |
| ACE | Angiotensin-converting enzyme; generates angiotensin II | Target of ACE inhibitors; KO models show altered vasoconstriction |
| ADRB2 | Beta-2 adrenergic receptor; mediates vasodilation | Counter-regulatory; polymorphisms affect vasoreactivity |
| ADRA1A | Alpha-1A adrenergic receptor; mediates vasoconstriction | Sympathetic regulation; KO models for blood pressure studies |
| AVP | Arginine vasopressin; vasoconstrictor hormone | Regulates blood pressure; KO models available |
| KCNMA1 | Large-conductance calcium-activated potassium channel; modulates vascular tone | Influences vasoconstriction; KO models show altered tone |
| CACNA1C | L-type calcium channel; mediates calcium influx in smooth muscle | Target of calcium channel blockers; KO models for vasoconstriction |
| RHOA | RhoA GTPase; promotes calcium sensitization | Enhances vasoconstriction; KO models for vascular studies |
| ROCK1 | Rho-associated kinase; mediates calcium sensitization | Involved in vasoconstriction; KO models available |
| PTGS2 | Cyclooxygenase-2; produces vasoactive prostanoids | Modulates vascular tone; KO models for inflammation studies |
| CYBA | Cytochrome b-245 alpha chain; component of NADPH oxidase | Generates ROS that enhance vasoconstriction; KO models for oxidative stress |
| GUCY1A1 | Soluble guanylate cyclase subunit; mediates NO-induced vasodilation | Counter-regulatory; KO models show hypertension |
How Is positive regulation of vasoconstriction Regulated?
Positive regulation of vasoconstriction is itself tightly regulated by multiple feedback mechanisms. Nitric oxide (NO) serves as a major counter-regulatory vasodilator; its production by eNOS is stimulated by shear stress and agonists like acetylcholine, and it diffuses to smooth muscle to promote relaxation. The renin-angiotensin-aldosterone system (RAAS) is a key hormonal cascade that enhances vasoconstriction; renin release is triggered by sympathetic activation, low sodium, or reduced renal perfusion, leading to angiotensin II generation and aldosterone secretion. Aldosterone antagonism has been shown to improve outcomes in heart failure, underscoring the importance of this regulation. Additionally, ageing and sex hormones modulate sympathetic neurocirculatory regulation, affecting vasoconstrictor responses. Renal autoregulation involves myogenic and tubuloglomerular feedback mechanisms that adjust vasoconstriction to maintain constant blood flow. Finally, hypoxic pulmonary vasoconstriction is regulated by oxygen tension and can be inhibited by carbon monoxide.
positive regulation of vasoconstriction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DAPK1 | Hypertension | Knockout and overexpression in vascular smooth muscle cells; blood pressure telemetry in mice |
| AGTR1 | Hypertension, heart failure | CRISPR KO in mice; angiotensin II infusion model |
| NOS3 | Hypertension, endothelial dysfunction | KO mice; measurement of vasoconstriction and NO bioavailability |
| EDN1 | Pulmonary hypertension | KO and transgenic overexpression; hypoxia-induced pulmonary hypertension model |
| CYBA | Oxidative stress-related vascular disease | KO mice; NADPH oxidase activity and vasoconstriction assays |
Hypertension and Cardiovascular Disease
Positive regulation of vasoconstriction is a central mechanism in the pathogenesis of hypertension. DAPK1 has been identified as a positive regulator of hypertension via induction of vasoconstriction, suggesting that targeting DAPK1 or its downstream effectors could lower blood pressure. The RAAS, through angiotensin II and aldosterone, promotes vasoconstriction and sodium retention; aldosterone antagonism improves outcomes in heart failure, highlighting the therapeutic potential of modulating this pathway. Renal autoregulation, which depends on vasoconstriction, is critical for maintaining glomerular filtration rate; its impairment can lead to kidney damage.
Septic Shock and Inflammation
In septic shock, excessive production of nitric oxide causes vasodilation and hypotension, but impaired NO signaling can also lead to enhanced vasoconstriction and organ ischemia. The balance between vasoconstrictor and vasodilator forces is critical; therapeutic strategies aim to restore vascular tone. Positive regulation of vasoconstriction may be maladaptive in this context, contributing to microvascular dysfunction.
Pulmonary Hypertension and Hypoxic Responses
Hypoxic pulmonary vasoconstriction is a protective reflex that diverts blood from poorly ventilated lung regions, but chronic hypoxia can lead to pulmonary hypertension. Carbon monoxide inhibits hypoxic pulmonary vasoconstriction in rats, suggesting that heme oxygenase-1 and CO may modulate this process. Endothelin-1 is a potent vasoconstrictor implicated in pulmonary arterial hypertension, and endothelin receptor antagonists are used clinically.
Ageing and Sex Differences
Ageing and sex significantly impact sympathetic neurocirculatory regulation, thereby influencing vasoconstrictor responses and cardiovascular risk. Older adults often exhibit increased sympathetic activity and enhanced vasoconstriction, contributing to hypertension. Sex hormones such as estrogen may modulate vascular tone, explaining some of the sex differences in cardiovascular disease prevalence.
From positive regulation of vasoconstriction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DAPK1 causally increase vasoconstriction? | DAPK1 knockout and overexpression in vascular smooth muscle cells; in vivo blood pressure measurement |
| What is the role of a specific point mutation in AGTR1 in vasoconstriction? | CRISPR point mutation knock-in mice; angiotensin II response |
| How does endothelial NOS3 affect vasoconstriction? | NOS3 knockout mice; vascular reactivity assays |
| Can overexpression of EDN1 induce pulmonary hypertension? | Transgenic overexpression of EDN1 in mice; hemodynamic measurements |
| What is the effect of a tagged knock-in of ROCK1 on its localization? | CRISPR knock-in of fluorescent tag; imaging of vascular smooth muscle |
| Does knockout of ADRA1A alter sympathetic vasoconstriction? | ADRA1A knockout mice; nerve stimulation and blood pressure telemetry |
How to Study the positive regulation of vasoconstriction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Wire myography | Vasoconstriction force in isolated arteries | Assess response to agonists in KO vs WT |
| Blood pressure telemetry | Arterial pressure in conscious animals | Long-term monitoring in genetic models |
| Calcium imaging | Intracellular calcium levels | Measure smooth muscle activation |
| Western blot | Protein expression and phosphorylation | Validate KO or overexpression |
| RNA-seq | Transcriptome changes | Identify pathways altered by gene manipulation |
| CRISPR library screening | Identify genes affecting vasoconstriction | High-throughput discovery of regulators |
| Nitric oxide assay | NO metabolites (nitrite/nitrate) | Assess endothelial function |
| Immunofluorescence | Protein localization in tissues | Validate knock-in tags |
CRISPR-Based Genetic Models
CRISPR/Cas9 technology enables the generation of knockout, knock-in, and point-mutation models to study genes involved in positive regulation of vasoconstriction. For example, DAPK1 knockout mice can be used to assess its role in hypertension and vasoconstriction. Knock-in of specific mutations in AGTR1 can reveal their impact on receptor function and blood pressure. Overexpression models via CRISPR activation or transgenic approaches can test gain-of-function effects.
Physiological Measurements of Vasoconstriction
Vasoconstriction can be measured ex vivo using wire myography or pressure myography on isolated arteries, and in vivo via blood pressure telemetry or Doppler flowmetry. These methods assess the response to vasoconstrictors like angiotensin II or endothelin-1, and can be combined with genetic models to establish causality [1,7].
Molecular and Cellular Assays
Intracellular calcium imaging, phosphorylation assays for myosin light chain, and RhoA/ROCK activity assays are used to dissect signaling pathways. Nitric oxide bioavailability can be measured using Griess reagent or fluorescent probes. These techniques help link genetic perturbations to molecular changes.
Omics and Bioinformatics
RNA-seq and proteomics can identify global changes in gene expression after genetic manipulation. CRISPR library screening can uncover novel regulators of vasoconstriction. Bioinformatics analysis of public datasets (e.g., GTEx, ENCODE) can prioritize candidate genes for functional studies.
How CRISPR Can Be Used to Study GO:0045907 positive regulation of vasoconstriction
Knockout
CRISPR knockout of genes such as DAPK1, AGTR1, or NOS3 in mice or cell lines can determine their necessity for positive regulation of vasoconstriction. For example, DAPK1 knockout may reduce hypertension and vasoconstrictor responses. Knockout of NOS3 leads to hypertension, confirming its role as a negative regulator.
Point Mutation
Point mutations can mimic human polymorphisms or disrupt specific phosphorylation sites. For instance, knock-in of a mutation in AGTR1 that affects ligand binding can reveal its impact on vasoconstriction. CRISPR base editing or prime editing enables precise point mutations without indels.
Knock-in
Knock-in of reporter tags (e.g., GFP) or epitope tags allows visualization and purification of proteins like ROCK1. Knock-in of human disease alleles into mouse models can create more relevant models for hypertension research.
Overexpression
Overexpression of candidate genes such as EDN1 or DAPK1 using CRISPR activation or transgenic approaches can test sufficiency for enhancing vasoconstriction. For example, EDN1 overexpression induces pulmonary hypertension in mice.
How EDITGENE Supports positive regulation of vasoconstriction Research
Researchers studying positive regulation of vasoconstriction-related genes often need to determine whether a candidate gene is causally involved in vascular tone regulation. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest in relevant cell types or animal models. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies, from design to validation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of vasoconstriction research.
Frequently Asked Questions About positive regulation of vasoconstriction
What is GO:0045907 positive regulation of vasoconstriction?
GO:0045907 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of vasoconstriction, the narrowing of blood vessels.
What genes are involved in positive regulation of vasoconstriction?
Key genes include DAPK1, AGTR1, EDN1, NOS3, REN, ACE, and ADRA1A, among others, as identified in published literature [1,5,6].
How does DAPK1 regulate vasoconstriction?
DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction, likely through modulation of calcium signaling or contractile machinery.
What is the role of nitric oxide in vasoconstriction?
Nitric oxide is a major vasodilator that counter-regulates vasoconstriction; reduced NO bioavailability enhances vasoconstrictor tone.
How is positive regulation of vasoconstriction studied?
It is studied using CRISPR knockout/knock-in models, myography, blood pressure telemetry, calcium imaging, and molecular assays [1,7].
What diseases are associated with abnormal vasoconstriction?
Hypertension, heart failure, septic shock, and pulmonary hypertension are associated with dysregulated vasoconstriction [1,4,5,6].
Does ageing affect vasoconstriction regulation?
Yes, ageing impacts sympathetic neurocirculatory regulation, leading to increased vasoconstrictor responses.
What is hypoxic pulmonary vasoconstriction?
It is a protective reflex that narrows pulmonary vessels in response to low oxygen to optimize ventilation-perfusion matching; it can be inhibited by carbon monoxide.
How does the renin-angiotensin-aldosterone system regulate vasoconstriction?
Angiotensin II directly constricts vessels, while aldosterone promotes sodium retention and sensitizes vessels; aldosterone antagonism benefits heart failure.
Can CRISPR be used to study vasoconstriction genes?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are powerful tools to establish causality and dissect mechanisms.
Conclusion
Positive regulation of vasoconstriction (GO:0045907) is a critical biological process that governs vascular tone and blood pressure. Its dysregulation underlies major cardiovascular diseases, making it a focal point for research. Advances in CRISPR-based genetic models and physiological assays are enabling precise dissection of the molecular players involved, such as DAPK1, AGTR1, and NOS3. Continued investigation promises to reveal new therapeutic targets for hypertension, heart failure, and related disorders.
References
- 1. Zhang X et al.. 2025. DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction.. Clin Sci (Lond) 139(12):667-81 PMID: 40454931
- 2. Klassen SA et al.. 2021. The impact of ageing and sex on sympathetic neurocirculatory regulation.. Semin Cell Dev Biol 116:72-81 PMID: 33468420
- 4. Yoo HY et al.. 2010. Inhibition of hypoxic pulmonary vasoconstriction of rats by carbon monoxide.. J Korean Med Sci 25(10):1411-7 PMID: 20890419
- 5. Thiemermann C. 1997. Nitric oxide and septic shock.. Gen Pharmacol 29(2):159-66 PMID: 9251894
- 6. Sethi R et al.. 2024. Evidence for Aldosterone Antagonism in Heart Failure.. Card Fail Rev 10:e15 PMID: 39588014
- 7. Carlström M et al.. 2015. Renal autoregulation in health and disease.. Physiol Rev 95(2):405-511 PMID: 25834230
